Hamdy 2005.

Methods	Design: parallel RCT Duration: May 2001 to January 2003 Follow up: 2 years
Participants	Setting: Single centre study Country: Egypt Living donor kidney transplant recipients Number (group 1/group 2): 132 (65/67) Mean age ± SD (years): group 1 (32.3 ± 10.3); group 2 (31.8 ± 8.6) Sex (M/F): group 1 (52/13); group 2 (47/20) Exclusions: requiring 2nd kidney transplantation; patients < 18 years; cases with pre‐transplant chemistries demonstrating a total serum cholesterol > 300 mg/dL; triglycerides > than 400 mg/dL; WBC < 4000/mm3 or platelets < 150,000/mm3; pre‐transplant positive lymphocytotoxic cross‐match test; > 50% DR mismatch
Interventions	Treatment group 1 SRL: 10 mg/d within 24 hours of transplant and for 3 days; then 5 mg/day for levels 6 to 12 ng/mL TAC: 0.03 mg/kg/d started on day 3 if CrCl > 50 mL/min targeting a 12‐h whole blood trough level of 3 to 7 ng/mL. Treatment group 2 SRL: 10 mg daily within 24 hours of transplant for levels of 10 to 15 ng/mL MMF 2 g/d Co‐interventions Basiliximab Prednisolone
Outcomes	Death (all causes) Graft loss censored for death Graft loss or death with a functioning graft BPAR GFR Infection (no CMV) Surgical adverse events Biochemical adverse events
Notes	Comparison: low dose versus high dose TOR‐1
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "A prospective, randomised controlled trial where they were divided into two groups"
Allocation concealment (selection bias)	Unclear risk	Quote: "A prospective, randomised controlled trial where they were divided into two groups"
Blinding of participants and personnel (performance bias) All outcomes	High risk	No blinding reported
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Primary outcomes were death and graft survival and these unlikely to be influenced by lack of blinding
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients accounted for
Selective reporting (reporting bias)	Low risk	Expected outcomes reported
Other bias	Unclear risk	No report of funding